Break­ing: FDA clears sec­ond Alzheimer's drug in 'foun­da­tion­al spark' for field

US reg­u­la­tors ap­proved Ei­sai and Bio­gen’s Alzheimer’s drug lecanemab, a land­mark mo­ment for the dis­ease and a sec­ond chance for the com­pa­nies af­ter their drug …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER